Literature DB >> 18205536

Postinfectious irritable bowel syndrome.

Andrew W DuPont1.   

Abstract

After acute bacterial gastroenteritis, up to one-third of patients will have prolonged gastrointestinal complaints, and a portion of those affected will meet the diagnostic criteria for postinfectious irritable bowel syndrome. After resolution of the acute infection, patients with postinfectious irritable bowel syndrome appear to have chronic mucosal immunologic dysregulation with altered intestinal permeability and motility that can lead to persistent intestinal symptoms. Both host- and pathogen-related factors, such as preexisting psychological disorders and duration of initial infection, have been associated with an increased risk for the development of postinfectious irritable bowel syndrome. Current treatments for postinfectious irritable bowel syndrome are typically targeted at specific symptoms, although studies evaluating therapies directed at preventing or reducing the duration of the initial infection are ongoing.

Entities:  

Mesh:

Year:  2008        PMID: 18205536     DOI: 10.1086/526774

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Management of the returning traveler with diarrhea.

Authors:  Philippe P H de Saussure
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 2.  Enterotoxigenic Escherichia coli Infections.

Authors:  James M Fleckenstein; F Matthew Kuhlmann
Journal:  Curr Infect Dis Rep       Date:  2019-03-04       Impact factor: 3.725

Review 3.  Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome.

Authors:  Hong-Yan Qin; Justin C Y Wu; Xu-Dong Tong; Joseph J Y Sung; Hong-Xi Xu; Zhao-Xiang Bian
Journal:  J Gastroenterol       Date:  2010-09-17       Impact factor: 7.527

4.  Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome.

Authors:  Erja Malinen; Lotta Krogius-Kurikka; Anna Lyra; Janne Nikkilä; Anne Jääskeläinen; Teemu Rinttilä; Terttu Vilpponen-Salmela; Atte Johannes von Wright; Airi Palva
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

5.  Cryptosporidium parvum isolate-dependent postinfectious jejunal hypersensitivity and mast cell accumulation in an immunocompetent rat model.

Authors:  Samira Khaldi; Gilles Gargala; Laetitia Le Goff; Simon Parey; Arnaud Francois; Jean Fioramonti; Jean-Jacques Ballet; Jean-Paul Dupont; Philippe Ducrotté; Loïc Favennec
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

6.  The Development of Irritable Bowel Syndrome: A Prospective Community-Based Cohort Study.

Authors:  Bernd Löwe; Ansgar Lohse; Viola Andresen; Eik Vettorazzi; Matthias Rose; Wiebke Broicher
Journal:  Am J Gastroenterol       Date:  2016-07-05       Impact factor: 10.864

7.  JCM-16021, a Chinese Herbal Formula, Attenuated Visceral Hyperalgesia in TNBS-Induced Postinflammatory Irritable Bowel Syndrome through Reducing Colonic EC Cell Hyperplasia and Serotonin Availability in Rats.

Authors:  Hong-Yan Qin; Hai-Tao Xiao; Fung-Ping Leung; Zhi-Jun Yang; Justin C Y Wu; Joseph J Y Sung; Hong-Xi Xu; Xu-Dong Tong; Zhao-Xiang Bian
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-10       Impact factor: 2.629

Review 8.  The interplay of the gut microbiome, bile acids, and volatile organic compounds.

Authors:  Nidhi M Sagar; Ian A Cree; James A Covington; Ramesh P Arasaradnam
Journal:  Gastroenterol Res Pract       Date:  2015-03-03       Impact factor: 2.260

9.  The gut microbiota and irritable bowel syndrome: friend or foe?

Authors:  Uday C Ghoshal; Ratnakar Shukla; Ujjala Ghoshal; Kok-Ann Gwee; Siew C Ng; Eamonn M M Quigley
Journal:  Int J Inflam       Date:  2012-04-22

10.  Relative risk of irritable bowel syndrome following acute gastroenteritis and associated risk factors.

Authors:  B K Kowalcyk; H M Smeets; P A Succop; N J De Wit; A H Havelaar
Journal:  Epidemiol Infect       Date:  2013-08-13       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.